| 1 |
34977548 | Rasagiline does not exacerbate autonomic blood pressure dysregulation in early or mild Parkinson's disease. | 2022 |
1 |
| 2 |
35203982 | Rasagiline Withdrawal Syndrome in Parkinson's Disease. | 2022 Feb 5 |
2 |
| 3 |
35447344 | The evaluation of N-propargylamine-2-aminotetralin as an inhibitor of monoamine oxidase. | 2022 Jul 1 |
2 |
| 4 |
33818516 | Evaluation of the combined activity of benzimidazole arylhydrazones as new anti-Parkinsonian agents: monoamine oxidase-B inhibition, neuroprotection and oxidative stress modulation. | 2021 Nov |
1 |
| 5 |
33887441 | Novel 1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-indene-4-thiol derivatives as potent selective human monoamine oxidase B inhibitors: Design, SAR development, and biological evaluation. | 2021 Jul 1 |
1 |
| 6 |
34290084 | Monoamine Oxidase-B Inhibition Facilitates α-Synuclein Secretion In Vitro and Delays Its Aggregation in rAAV-Based Rat Models of Parkinson's Disease. | 2021 Sep 1 |
1 |
| 7 |
34352710 | Biphenylpiperazine Based MAO Inhibitors: Synthesis, Biological Evaluation, Reversibility and Molecular Modeling Studies. | 2021 Oct |
1 |
| 8 |
34562673 | Discovery of 3,4-dichloro-N-(1H-indol-5-yl)benzamide: A highly potent, selective, and competitive hMAO-B inhibitor with high BBB permeability profile and neuroprotective action. | 2021 Nov |
1 |
| 9 |
34784871 | How to optimize the effectiveness and safety of Parkinson's disease therapy? - a systematic review of drugs interactions with food and dietary supplements. | 2021 Nov 16 |
1 |
| 10 |
32037726 | Coumarin-Rasagiline Hybrids as Potent and Selective hMAO-B Inhibitors, Antioxidants, and Neuroprotective Agents. | 2020 Mar 18 |
1 |
| 11 |
32250219 | Exploring the Multifunctional Neuroprotective Promise of Rasagiline Derivatives for Multi-Dysfunctional Alzheimer's Disease. | 2020 |
1 |
| 12 |
32378642 | [Pharmacological properties and clinical efficacy of rasagiline mesylate (Azilect®)]. | 2020 |
1 |
| 13 |
32652406 | Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease. | 2020 Sep 15 |
1 |
| 14 |
32752896 | Discovery of N-(1-(3-fluorobenzoyl)-1H-indol-5-yl)pyrazine-2-carboxamide: a novel, selective, and competitive indole-based lead inhibitor for human monoamine oxidase B. | 2020 Dec |
1 |
| 15 |
32858935 | Hydride Abstraction as the Rate-Limiting Step of the Irreversible Inhibition of Monoamine Oxidase B by Rasagiline and Selegiline: A Computational Empirical Valence Bond Study. | 2020 Aug 26 |
1 |
| 16 |
33375412 | First Synthesis of Racemic Trans Propargylamino-Donepezil, a Pleiotrope Agent Able to Both Inhibit AChE and MAO-B, with Potential Interest against Alzheimer's Disease. | 2020 Dec 27 |
1 |
| 17 |
30160213 | Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside. | 2019 |
1 |
| 18 |
30192007 | Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial. | 2019 Feb |
2 |
| 19 |
30205936 | Rasagiline monotherapy in early Parkinson's disease: A phase 3, randomized study in Japan. | 2019 Mar |
1 |
| 20 |
30689042 | Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson's disease. | 2019 Mar |
1 |
| 21 |
30877626 | Polycaprolactone-based neurotherapeutic delivery of rasagiline targeting behavioral and biochemical deficits in Parkinson's disease. | 2019 Oct |
1 |
| 22 |
31264403 | Computational Insight into the Mechanism of the Irreversible Inhibition of Monoamine Oxidase Enzymes by the Antiparkinsonian Propargylamine Inhibitors Rasagiline and Selegiline. | 2019 Aug 21 |
2 |
| 23 |
31421966 | Rasagiline derivatives combined with histamine H3 receptor properties. | 2019 Oct 1 |
2 |
| 24 |
31795034 | Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [18F]THK5351 uptake in progressive supranuclear palsy. | 2019 |
2 |
| 25 |
29159774 | Pharmacokinetics, Pharmacodynamics, and Safety of Rasagiline Transdermal Patch: A Preliminary Study in Healthy Chinese Subjects. | 2018 Feb |
1 |
| 26 |
29279995 | Type A and B monoamine oxidases distinctly modulate signal transduction pathway and gene expression to regulate brain function and survival of neurons. | 2018 Nov |
1 |
| 27 |
29339253 | Design, synthesis and bioevalucation of novel 2,3-dihydro-1H-inden-1-amine derivatives as potent and selective human monoamine oxidase B inhibitors based on rasagiline. | 2018 Feb 10 |
4 |
| 28 |
29417334 | Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease. | 2018 Nov |
2 |
| 29 |
29464559 | Monoamine Oxidases. | 2018 |
1 |
| 30 |
29477356 | Simultaneous controlled iontophoretic delivery of pramipexole and rasagiline in vitro and in vivo: Transdermal polypharmacy to treat Parkinson's disease. | 2018 Jun |
1 |
| 31 |
29748109 | Efficacy and safety of adjunctive rasagiline in Japanese Parkinson's disease patients with wearing-off phenomena: A phase 2/3, randomized, double-blind, placebo-controlled, multicenter study. | 2018 Aug |
1 |
| 32 |
29847694 | A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease. | 2018 Sep |
1 |
| 33 |
29955193 | Interaction between Monoamine Oxidase B Inhibitors and Selective Serotonin Reuptake Inhibitors. | 2018 May-Jun |
1 |
| 34 |
29956417 | Rasagiline, an inhibitor of MAO-B, decreases colonic motility through elevating colonic dopamine content. | 2018 Nov |
1 |
| 35 |
30341696 | Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases. | 2018 Nov |
1 |
| 36 |
30534374 | Efficacy and safety of rasagiline in Chinese patients with early Parkinson's disease: a randomized, double-blind, parallel, placebo-controlled, fixed-dose study. | 2018 |
1 |
| 37 |
28148284 | Rasagiline-induced severe recurrent hypoglycemia in a young woman without diabetes: a case report. | 2017 Feb 2 |
1 |
| 38 |
28293967 | Efficacy of rasagiline for the treatment of Parkinson's disease: an updated meta-analysis. | 2017 Aug |
1 |
| 39 |
28299453 | Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease. | 2017 Jun |
1 |
| 40 |
28301816 | MAO enzymes inhibitory activity of new benzimidazole derivatives including hydrazone and propargyl side chains. | 2017 May 5 |
1 |
| 41 |
28550482 | Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study. | 2017 Jun |
2 |
| 42 |
28577058 | Type B and A monoamine oxidase and their inhibitors regulate the gene expression of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells: different signal pathways for neuroprotection by selegiline and rasagiline. | 2017 Sep |
5 |
| 43 |
28682929 | Determination of Monoamine Oxidase A and B Activity in Long-Term Treated Patients With Parkinson Disease. | 2017 Sep/Oct |
3 |
| 44 |
28923922 | TrkB neurotrophic activities are blocked by α-synuclein, triggering dopaminergic cell death in Parkinson's disease. | 2017 Oct 3 |
1 |
| 45 |
30566307 | Anti-parkinsonian drugs today. | 2017 Jan |
1 |
| 46 |
25604428 | Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression. | 2016 Feb |
2 |
| 47 |
26897020 | Erratum to: Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline. | 2016 Apr |
1 |
| 48 |
27060436 | Simultaneous bioanalysis of rasagiline and its major metabolites in human plasma by LC-MS/MS: Application to a clinical pharmacokinetic study. | 2016 Jun 5 |
2 |
| 49 |
27089850 | Free-water and BOLD imaging changes in Parkinson's disease patients chronically treated with a MAO-B inhibitor. | 2016 Aug |
1 |
| 50 |
27230855 | PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy. | 2016 Aug |
1 |